Rating Rationale
December 22, 2022 | Mumbai
Enaltec Labs Private Limited
Ratings continues on 'Watch Developing'; rated amount enhanced for bank debt
 
Rating Action
Total Bank Loan Facilities RatedRs.78 Crore (Enhanced from Rs.38.5 Crore)
Long Term RatingCRISIL B/Watch Developing (Continues on 'Rating Watch with Developing Implications')
Short Term RatingCRISIL A4/Watch Developing (Continues on 'Rating Watch with Developing Implications')
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings’ ratings on the bank facilities of Enaltec Labs Private Limited (ELPL) continues on 'Rating Watch with Developing Implications'

 

The ratings action follows acquisition of majority stake in ELPL by La Renon Healthcare Pvt Ltd (LRHPL, Rated CRISIL A-/Positive/CRISIL A2+’). LRHPL is not currently undertaking the complete management of ELPL and has not provided any financial support to ELPL yet. However, maybe provide the same in near future. CRISIL will monitor these developments and will remove the rating from Watch and take a final rating action post clarity on the financial, operational and managerial support from LRHPL.

 

The ratings continue to reflect the working capital-intensive operations of the company, its subdued financial risk profile, modest scale of operations amid intense competition and volatile operating margin. These weaknesses are partially offset by the extensive experience of the promoters in the pharmaceutical industry.

Analytical Approach

Unsecured loan has been treated as debt.

Key Rating Drivers & Detailed Description

Weaknesses:

  • Working capital-intensive operations: Gross current assets were at 291 days as on March 31, 2022, on account of sizeable raw material and work-in-progress inventory of 107 days. The receivables were moderate at 79 days. Working capital is funded by stretching credit from suppliers and high dependence on bank lines. Management of the working capital cycle will remain a key monitorable.

 

  • Subdued financial risk profile: The total outside liabilities to adjusted networth (TOLANW) ratio and gearing were high at 8.75 times and 5.48 times, respectively, as on March 31, 2022, on account of large, debt-funded capital expenditure (capex) in the near past and high dependence on working capital debt. With increase in bank debt, gearing is expected to increase. The interest coverage was subdued at 0.3 time for fiscal 2022 because of low operating margin and hence cash losses.

 

  • Modest scale amid intense competition: Revenue was modest Rs 128 crore in fiscal 2022. The Indian active pharmaceutical ingredient (API) industry has a large number of organized and unorganised players, on account of low entry barrier. The competition restricts bargaining power with customers and suppliers, leading to low profitability. Due to capital expenditure in the past fiscal, revenue is expected to increase over the medium term.

 

  • Volatile operating margin: Operating margin fluctuated widely in the three fiscals ended March 31, 2022, on account of volatility in the revenue mix. The company incurred an operating loss in fiscal 2020 because of delay in stabilisation of operations at the newly set-up manufacturing unit in Pithampur, Madhya Pradesh. Operating margin was at 0.8% in fiscal 2022.

 

Strengths:

  • Extensive industry experience of the promoters: The promoters have experience of more than two decades in the pharmaceutical industry, which has given them a sound understanding of the industry and helped them to continuously evolve the company and develop new products. Exports contribute around 75% to revenue. In the domestic market, the company has a sizeable customer base, comprising large pharmaceutical companies, with which it has healthy relationships.

Liquidity: Poor

Liquidity is poor with weak cash accruals in fiscal 2023 and fiscal 2024, which should be tightly matched against the repayment obligations of Rs. 13.8 crore and Rs.6.3 crores, respectively. The fund-based limit of Rs 43 crore was utilised at an average of 95% during the 12 months through June 2022.

Rating Sensitivity factors

Upward factors

  • Sustained growth in revenue and operating margin, leading to cash accrual above Rs 15 crore
  • Improvement in liquidity or clear articulation of financial support from LRHPL

 

Downward factors

  • Decline in revenue or in operating margin below 5% leading to continued cash losses
  • Severe stretch in the working capital cycle, impacting the liquidity further

About the Company

ELPL was incorporated in 2006 and is promoted by Mr Anand Shah and Mr Susheel Koul. The company manufactures bulk drugs and undertakes research and development on API for domestic and global clients. It has manufacturing units at Ambernath, Maharashtra and Pithampur, Madhya Pradesh.

Key Financial Indicators

As on / for the period ended March 31

 

2022

2021

Operating income

Rs crore

128.1

115.16

Reported profit after tax

Rs crore

-15.63

-11.7

PAT margin

%

-12.2

-10.2

Adjusted debt/Adjusted networth

Times

5.48

2.15

Interest coverage

Times

0.3

0.85

 

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisil.com/complexity-levels. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon rate (%)

Maturity

date

Issue size

(Rs crore)

Complexity

level

Rating assigned

with outlook

NA

Cash Credit

NA

NA

NA

3.5

NA

CRISIL B/Watch Developing

NA

Cash Credit

NA

NA

NA

3.5

NA

CRISIL B/Watch Developing

NA

Export Packing Credit

NA

NA

NA

6

NA

CRISIL B/Watch Developing

NA

Letter of Credit

NA

NA

NA

4.65

NA

CRISIL A4/Watch Developing

NA

Letter of Credit

NA

NA

NA

6

NA

CRISIL A4/Watch Developing

NA

Packing Credit

NA

NA

NA

15

NA

CRISIL B/Watch Developing

NA

Post Shipment Credit

NA

NA

NA

15

NA

CRISIL B/Watch Developing

NA

Long Term Loan

NA

NA

Jul-23

3.33

NA

CRISIL B/Watch Developing

NA

Long Term Loan

NA

NA

Mar-23

0.59

NA

CRISIL B/Watch Developing

NA

Long Term Loan

NA

NA

May-23

0.08

NA

CRISIL B/Watch Developing

NA

Long Term Loan

NA

NA

Aug-23

0.02

NA

CRISIL B/Watch Developing

NA

Long Term Loan

NA

NA

Dec-26

4.00

NA

CRISIL B/Watch Developing

NA

Long Term Loan

NA

NA

Feb-26

7.43

NA

CRISIL B/Watch Developing

NA

Long Term Loan

NA

NA

Jun-23

3.12

NA

CRISIL B/Watch Developing

NA

Long Term Loan

NA

NA

Sep-26

2.07

NA

CRISIL B/Watch Developing

NA

Proposed Fund-Based Bank Limits

NA

NA

NA

2.23

NA

CRISIL B/Watch Developing

NA

Proposed Fund-Based Bank Limits

NA

NA

NA

1.48

NA

CRISIL B/Watch Developing

 

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 67.35 CRISIL B/Watch Developing 05-12-22 CRISIL B/Watch Developing 06-09-21 CRISIL B/Stable 21-10-20 CRISIL D 30-09-19 CRISIL A3+ / CRISIL BBB/Negative CRISIL A3+ / CRISIL BBB/Stable
      --   -- 16-04-21 CRISIL B/Stable 21-07-20 CRISIL B/Stable / CRISIL A4   -- --
      --   -- 22-02-21 CRISIL B/Stable 26-03-20 CRISIL BB /Stable / CRISIL A4+ (Issuer Not Cooperating)*   -- --
Non-Fund Based Facilities ST 10.65 CRISIL A4/Watch Developing 05-12-22 CRISIL A4/Watch Developing 06-09-21 CRISIL A4 21-10-20 CRISIL D 30-09-19 CRISIL A3+ CRISIL A3+
      --   -- 16-04-21 CRISIL A4 21-07-20 CRISIL A4   -- --
      --   -- 22-02-21 CRISIL A4 26-03-20 CRISIL A4+ (Issuer Not Cooperating)*   -- --
All amounts are in Rs.Cr.
* - Issuer did not cooperate; based on best-available information
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Cash Credit 3.5 Union Bank of India CRISIL B/Watch Developing
Cash Credit 3.5 Axis Bank Limited CRISIL B/Watch Developing
Export Packing Credit 6 Axis Bank Limited CRISIL B/Watch Developing
Letter of Credit 4.65 Union Bank of India CRISIL A4/Watch Developing
Letter of Credit 6 Axis Bank Limited CRISIL A4/Watch Developing
Long Term Loan 2.07 Saraswat Bank CRISIL B/Watch Developing
Long Term Loan 3.12 Unity Small Finance Bank Limited CRISIL B/Watch Developing
Long Term Loan 7.43 Union Bank of India CRISIL B/Watch Developing
Long Term Loan 4 Axis Bank Limited CRISIL B/Watch Developing
Long Term Loan 0.59 Axis Bank Limited CRISIL B/Watch Developing
Long Term Loan 0.02 Axis Bank Limited CRISIL B/Watch Developing
Long Term Loan 0.08 Axis Bank Limited CRISIL B/Watch Developing
Long Term Loan 3.33 Axis Bank Limited CRISIL B/Watch Developing
Packing Credit 15 Union Bank of India CRISIL B/Watch Developing
Post Shipment Credit 15 Saraswat Bank CRISIL B/Watch Developing
Proposed Fund-Based Bank Limits 2.23 Not Applicable CRISIL B/Watch Developing
Proposed Fund-Based Bank Limits 1.48 Not Applicable CRISIL B/Watch Developing

This Annexure has been updated on 22-Dec-22 in line with the lender-wise facility details as on 30-Jul-21 received from the rated entity.

Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Assessing Information Adequacy Risk
CRISILs Bank Loan Ratings
The Rating Process

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Jaya Mirpuri
Director
CRISIL Ratings Limited
D:+91 20 4018 1926
jaya.mirpuri@crisil.com


Ankita Gupta
Associate Director
CRISIL Ratings Limited
D:+91 22 4097 8104
ankita.gupta@crisil.com


RAJ GUDHKA
Management Trainee
CRISIL Ratings Limited
B:+91 22 3342 3000
RAJ.GUDHKA@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html